By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bayhill Therapeutics, Inc. 

3400 West Bayshore Road

Palo Alto  California  94303  U.S.A.
Phone: n/a Fax: n/a



Company News
Bayhill Therapeutics, Inc. Announces the Successful Clearance of an IND for BHT-3034 for the Treatment of Myasthenia Gravis 3/2/2011 9:12:02 AM
Bayhill Therapeutics, Inc. to Present Correlation of Antibodies with Clinical Response to Treatment with BHT-3009 in Multiple Sclerosis 10/14/2010 8:09:10 AM
Bayhill Therapeutics, Inc. Enters Exclusive, Worldwide Collaboration with Genentech, Inc. (DNA) (JOBS) for BHT-3021 in Type 1 Diabetes; Deal Could Potentially Exceed $350M 6/10/2009 7:22:53 AM
Bayhill Therapeutics, Inc. Founder Lawrence Steinman, M.D. Recognized for Leadership in Multiple Sclerosis 3/16/2009 10:01:06 AM
Bayhill Therapeutics, Inc. to Participate in Interactive Workshop at BIO-Europe Spring(R) 2009 3/12/2009 8:49:30 AM
Bayhill Therapeutics, Inc. to Present Phase II Follow-up Data on BHT-3009 for Treatment of Multiple Sclerosis 3/9/2009 8:49:19 AM
Bayhill Therapeutics, Inc. and The Juvenile Diabetes Research Foundation Announce Research Collaboration for the Clinical Development of a Novel Immunotherapeutic DNA Vaccine for Type 1 Diabetes 10/30/2008 10:25:25 AM
Bayhill Therapeutics, Inc. Withdraws IPO Plans 6/30/2008 7:07:18 AM
Bayhill Therapeutics, Inc. Presents Data From a Phase II Trial of BHT-3009 in Multiple Sclerosis at American Academy of Neurology 60th Annual Meeting 4/17/2008 10:02:56 AM
Bayhill Therapeutics, Inc. Announces Presentation of MS Drug Candidate BHT-3009 at American Academy of Neurology 60th Annual Meeting 4/11/2008 8:59:01 AM